Yellow tea polysaccharides protect against non-alcoholic fatty liver disease via regulation of gut microbiota and bile acid metabolism in mice

被引:2
|
作者
Huang, Yuzhe [1 ,2 ,3 ,4 ]
Chen, Hao [1 ,4 ]
Chen, Jielin [1 ,4 ]
Wu, Qingxi [1 ,4 ]
Zhang, Wenna [1 ,4 ]
Li, Daxiang [5 ]
Lu, Yongming [1 ,4 ]
Chen, Yan [1 ,4 ]
机构
[1] Anhui Univ, Sch Life Sci, Hefei 230601, Anhui, Peoples R China
[2] Anhui Univ Chinese Med, Dept Pharm, Hefei 230012, Anhui, Peoples R China
[3] Anhui Acad Chinese Med, Inst Pharmaceut, Hefei 230012, Anhui, Peoples R China
[4] Key Lab Ecol Engn & Biotechnol Anhui Prov, Hefei 230601, Peoples R China
[5] Anhui Agr Univ, Sch Tea & Food Sci, State Key Lab Tea Plant Biol & Utilizat, Hefei 230036, Anhui, Peoples R China
关键词
Yellow tea; Polysaccharies; NAFLD; Targeted metabolomics; Gut microbiota; RECEPTOR;
D O I
10.1016/j.phymed.2024.155919
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Background: Nonalcoholic fatty liver disease (NAFLD) is a major clinical and global public health issue, with no specific pharmacological treatment available. Currently, there is a lack of approved drugs for the clinical treatment of NAFLD. Large-leaf yellow tea polysaccharides (YTP) is a natural biomacromolecule with excellent prebiotic properties and significant therapeutic effects on multiple metabolic diseases. However, the specific mechanisms by which YTP regulates NAFLD remain unclear. Purpose: This study aims to explore the prebiotic effects of YTP and the potential mechanisms by which it inhibits hepatic cholesterol accumulation in NAFLD mice. Methods: The effects of YTP on lipid accumulation were evaluated in NAFLD mice through obesity trait analysis and bile acids (BAs) metabolism assessment. Additionally, fecal microbiota transplantation (FMT) was performed, and high-throughput sequencing was employed to investigate the mechanisms underlying YTP's regulatory effects on gut microbiota and BA metabolism. Results: Our study demonstrated that YTP altered the constitution of colonic BA, particularly increasing the levels of conjugated BA and non-12OH BA, which suppressed ileum FXR receptors and hepatic BA reabsorption, facilitated BA synthesis, and fecal BA excretion. The modifications were characterized by a decrease in the levels of FXR, FGF15, FGFR4, and ASBT proteins, and an increase in the levels of Cyp7a1 and Cyp27a1 proteins. YTP might affect enterohepatic circulation and by the activated the hepatic FXR-SHP pathway. Meanwhile, YTP reshaped the intestinal microbiome structure by decreasing BSH-producing genera and increasing taurine metabolism genera. The correlation analysis implied that Muribaculaceae, Pseudomonas, acterium_coprostanoligenes_group, Clostridiales, Lachnospiraceae_NK4A136_group, Delftia, Dubosiella, and Romboutsia were strongly correlated with specific BA monomers. Conclusions: YTP modulates bile salt hydrolase-related microbial genera to activate alternative bile acid synthesis pathways, thereby inhibiting NAFLD progression. These results suggest that YTP may serve as a potential pro- biotic formulation, offering a feasible dietary intervention for NAFLD.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota
    Han, Ruiting
    Ma, Junli
    Li, Houkai
    FRONTIERS OF MEDICINE, 2018, 12 (06) : 645 - 657
  • [22] Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients
    Perez-Rubio, Alvaro
    Soluyanova, Polina
    Moro, Erika
    Quintas, Guillermo
    Rienda, Ivan
    Perianez, Maria Dolores
    Painel, Andres
    Vizuete, Jose
    Perez-Rojas, Judith
    Castell, Jose V.
    Trullenque-Juan, Ramon
    Pareja, Eugenia
    Jover, Ramiro
    NUTRIENTS, 2023, 15 (14)
  • [23] Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents
    Tokuhara, Daisuke
    FRONTIERS IN NUTRITION, 2021, 8
  • [24] Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota
    Ruiting Han
    Junli Ma
    Houkai Li
    Frontiers of Medicine, 2018, 12 : 645 - 657
  • [25] Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota
    Doulberis, Michael
    Kotronis, Georgios
    Gialamprinou, Dimitra
    Kountouras, Jannis
    Katsinelos, Panagiotis
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 71 : 182 - 197
  • [26] Shenling Baizhu San ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites
    Chen, Dongliang
    Wang, Yuanfei
    Yang, Jianmei
    Ou, Wanyi
    Lin, Guiru
    Zeng, Ze
    Lu, Xiaomin
    Chen, Zumin
    Zou, Lili
    Tian, Yaling
    Wu, Aiping
    Keating, Shelley E.
    Yang, Qinhe
    Lin, Chenli
    Liang, Yinji
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [27] Microbiota and non-alcoholic fatty liver disease
    Link, A.
    Thon, C.
    Sydor, S.
    Canbay, A.
    GASTROENTEROLOGE, 2019, 14 (03): : 179 - 184
  • [28] Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut-Liver Axis
    Chen, Xiang
    Liu, Menghan
    Tang, Jun
    Wang, Ning
    Feng, Yibin
    Ma, Haotian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [29] Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis
    Yang, Chao
    Wan, Min
    Xu, Dengfeng
    Pan, Da
    Xia, Hui
    Yang, Ligang
    Sun, Guiju
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [30] The role of gut microbiota in the occurrence and progression of non-alcoholic fatty liver disease
    Mai, Huanzhuo
    Yang, Xing
    Xie, Yulan
    Zhou, Jie
    Wang, Qing
    Wei, Yiru
    Yang, Yuecong
    Lu, Dongjia
    Ye, Li
    Cui, Ping
    Liang, Hao
    Huang, Jiegang
    FRONTIERS IN MICROBIOLOGY, 2024, 14